Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00231335|
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : December 7, 2010
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Schizoaffective Disorder||Drug: escitalopram||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study|
|Study Start Date :||March 2006|
|Actual Study Completion Date :||July 2007|
- Reduction of severity of symptoms defined as decrease of >20% from baseline to final evaluation on the PANSS total score.
- Changes on depression/anxiety dimensions of PANSS subscales defined as decrease of >20% from baseline to final evaluation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00231335
|Principal Investigator:||Dragan Bugarski-Kirola, MD||Emory University|